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Tratamento da rejeição endotelial pós-ceratoplastia penetrante
através da associação do pulso de metilprednisolona intravenosa
com acetato de prednisolona  tópico. Seguimento de um ano
ABSTRACT
Objective: To analyze the recovery of visual acuity (VA) and graft survival after first episode of endothelial rejection in penetrating
keratoplasty (PKP) treated with intravenous (IV) and topic corticosteroid. Methods:  Interventional, prospective, non-comparative case
series study evolving 32 PKP patients in one year follow up, who presented first episode of corneal endothelial rejection. The patients were
submitted to 500 mg IV injection of methylprednisolone in association with topical prednisolone. Main outcome measures included VA
recovery and corneal edema regression. Second outcome included new rejections and graft failure. Multivariate analysis techniques were
used to estimate rates of graft outcome events and the impact of risk factors. Results: A total of 32 eyes from 32 patients (13 male and 19
female) were included in the study. The mean VA (in number of letters) before rejection was 48 (22 to 88 letters).  Patients treated within
7 days or less of initial symptoms had better VA recovery, corneal edema regression  and less graft failure (p<0.001). Patients with
previous ocular surgery had worse VA recovery and more graft failure (p<0.047).  Conclusion: The association between the other risk
factors and the outcomes did not reach statistical significance in the multivariate model because of the small numbers of patients.
Methylprednisolone in association with topical prednisolone is an alternative treatment for graft rejection. Our study showed that
patients treated within 7 days of symptoms and no previous anterior segment surgery had better visual outcome and graft survival after
treatment.
Keywords: Keratoplasty, penetrating; Graft rejection; Adrenal cortex hormones; Risk factors; Methylprednisolone/administration
& dosage; Methylprednisolone/therapeutic use; Treatment outcome
RESUMO
Objetivo: Analisar a recuperação da acuidade visual (AV) e sobrevivência do enxerto após primeiro episódio de rejeição endotelial
em ceratoplastia penetrante (PK) em pacientes submetidos ao corticóide intravenoso (IV) associado ao tópico. Métodos:  Estudo
descritivo, prospectivo, tipo série de casos envolvendo 32 pacientes com PK tratados com 2 doses de 500mg de metilprednisolona IV
(com intervalo de 1 semana) associado ao acetato de prednisolona 1%. O parâmetro principal analisado foi a recuperação da AV e
a regressão do edema corneano. O parâmetro secundário utilizado foi a recorrência das rejeições e a falência do enxerto. Resulta-
dos: Um total de 32 olhos de 32 pacientes foram incluídos no estudo (13 homens e 19 mulheres). A média da AV (em número de
letras) foi 48. Pacientes tratados dentro de 7 dias ou menos após o surgimento dos sintomas apresentaram melhor recuperação da
AV e menor falência do enxerto (p<0,001). Pacientes com antecedente de cirurgia ocular anterior à PK apresentaram pior recupe-
ração da AV e maior índice de falência do enxerto. Conclusão: A associação entre os outros fatores de risco não atingiram significância
estatística devido ao baixo número de pacientes do estudo. A metilprednisolona IV em associação com a prednisolona tópica pode
ser uma alternativa para o tratamento da rejeição endotelial do enxerto. Nossos resultados sugerem que pacientes tratados dentro
de 7 dias do início dos sintomas e a ausência de cirurgia ocular prévia apresentam melhor recuperação da AV e melhor sobrevivên-
cia do enxerto.
Descritores: Ceratoplastia penetrante/quimioterapia; Rejeição de enxerto; Corticosteróides; Fatores de risco;  Metilprednisolona/
administração & dosagem; Metilprednisolona/uso terapêutico; Resultado de tratamento
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INTRODUCTION
Despite the exciting progress in corneal surgery, PKremains the most common form of cornealtransplantation in the world at present, and although
PK may diminish in importance in the future, it will remain the
default or procedure of choice for some eyes (1). The mean 5-
year survival according to the Australian Corneal Graft Regis-
try is 73% and 31% of all failures are due to rejection(2). The
Singapore Corneal Transplant Study (SCTS) report 85% of graft
survival in 10 years, in the absence of any postoperative risk
factor. A lower graft survival (34% at 10 years) was reported in
presence of one postoperative risk factor, including infection,
rejection, disease recurrence, eyelid or glaucoma surgery, or a
repeat graft(3).  Although the preoperative risk factors for graft
failure cannot be modified, the prevention or early detection of
postoperative risk factors for graft failure may be important for
prolonging graft survival. The risk factors for graft survival can
be divided into recipient, donor, and postoperative risk factors.
Recipient diagnosis is the most important preoperative risk fac-
tor, with grafts for keratoconus having the best survival rate,
and grafts for endothelial disease, corneal opacity, and ipsilat-
eral graft failure having a worse survival rate and survival also
is worsened by active or previous intraocular inflammation or
ocular hypertension(4). After surgery, allograft rejection consis-
tently has been found to be a leading cause of graft failure and
effective treatment of corneal graft rejection is therefore vital.
Although corticosteroids were the mainstay of treatment of cor-
neal graft rejection, there are no consensus on optimal methods of
administration, dosage, or treatment duration(5,6). Evidence avail-
able so far suggests a beneficial role of intravenous (i.v.) methyl-
prednisolone when combined with topical steroids over frequent
topical steroids alone, and also over oral steroids in combination
with topical steroids in selected cases(7). The purpose of this study
was to assess the efficacy of treating corneal endothelial allograft
rejection with a double pulse of 500mg i.v. methylprednisolone
and topical 1% prednisolone acetate and correlate the findings
with the recipient, donor, and postoperative risk factors.
METHODS
Patient eligibility
In this interventional, prospective, non-comparative case
series study, 32 patients who underwent penetrating kerato-
plasty (with single suture technique) were enrolled. We did not
exclude patients with ocular surgery prior to PK. The study was
conducted from January 2010 through December 2010 in the
Department of Ophthalmology at the Hospital das Clínicas -
State University of Campinas. All patients were engaged in an
informed consent process before any study procedures were
carried out. The study complied with the tenets of the Declara-
tion of Helsinki and was approved by the State University of
Campinas Ethical Committee. Patients were included if they
presented with their first episode of corneal transplant endot-
helial rejection. Corneal graft rejection was defined as the ap-
pearance of one or more of the following: an endothelial rejec-
tion line, new keratic precipitates, anterior chamber cells, and/
or corneal edema in the donor graft not previously noted. The
medical records of the eligible patients were reviewed and rel-
evant demographic and clinical data such as surgical proce-
dure and information about postoperative follow up were con-
sidered for their association with the graft outcome.
Study medication
Eyes that developed rejection were treated 2 pulses of
500mg i.v. Methylprednisolone (Solu-Medrol® Pfizer), with one
week interval associated with topical corticosteroid (Predforte
®- prednisolone acetate ophthalmic suspension 1% Allergan).
The topical corticosteroid was used hourly (1/1 hour) for 1 week.
After 1 week, patients were treated with topical prednisolone
acetate 1.0% every 2 hours (2/2 hours) for 2 more weeks, after
which therapy was slowly tapered over 6 months. (The average
corticosteroid regimen was as follows: 8 drops per 24 hours for 2
weeks, 6 drops per 24 hours for 2 weeks, 5 drops per 24 hours for
2 weeks, 4 drops per 24 hours for 1 month, 3 drops per 24 hours
for 3 months, 2 drops per 24 hours for 3 months, and then 1 drop
per 24 hours for 3 months.)
Examination
All patients underwent complete ophthalmological exami-
nation , including ETDRS best-corrected visual acuity (BCVA)
testing, intraocular pressure  measured with an applanation
tonometer, slit-lamp examination, and corneal epithelial dam-
age using the fluorescein staining test.  Follow-up examinations
were performed weekly during the first month after the rejec-
tion episode, and monthly during the next 5 months and trimestral
during the following 6 months. The ETDRS chart was used to
determine the BCVA, and decimal values were converted to their
logarithm for statistical analysis. Corneal edema was graded by
visual slit-lamp inspection according to a corneal clarity score(8)
with the following ratings: 1 - clear cornea., 2 - diffuse corneal
edema with relative clarity to visualize underlying structures,  3
- relatively opaque cornea with some visualization of underlying
structures and 4 -  very opaque cornea, difficult to visualize un-
derlying structures.
Outcome measure
Main outcome measures included BCVA before treatment
in comparison to the most recent follow-up and corneal edema
regression. Second outcome included new rejections and graft
failure during follow up.  The criteria for graft failure were irre-
versible graft stromal edema and corneal opacification (within
one year of follow up).
Statistical analysis
In order to estimate rates of graft outcome events and the
impact of risk factors we used the SPSS for Windows (version 19,
IBM).  T Student and qui-square test were used for the vari-
ables. Values p<0,05 was considered statistically significant.
RESULTS
Demographic and baseline data
Between january 2010 and december 2010, a total of 32
eyes from 32 patients (13 male and 19 female) with mean age
48.78 +/- 19.4 years were included in the study. The primary pre-
operative diagnoses for the 32 eyes undergoing PK were as fol-
lows in Table 1.
The mean VA (in number of letters) before rejection was
48 (22 to 88 letters). Characteristics of the patients such as days
of symptoms (until diagnoses and treatment), previous ocular
surgical history (in our study, all surgeries were
phacoemulsification), ocular pathologies, systemic diseases,
corneal vascularization, epithelial defect, anterior synechia,
loosen or broken sutures within 6 months of post-operative period
and the presence of penetrating keratoplasty in the other eye
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were registered and showed in Table 2. Additional data were
collected and graduated through record review.
Outcomes
The primary outcome measurement was the recovery of
BCVA  and corneal edema regression. Eight eyes from 32 did
not recover previous BCVA and remained with corneal edema.
The secondary outcome measurement was the development of
new endothelial rejections and graft failures. 12 eyes from 32
presented new rejections, and 8 eyes from 32 were considered
graft failures. By Fisher exact test, there was no statistically
significant correlation between the outcomes (primary and
secondary) with corneal vascularization, anterior synechia,
epithelial defect and presence of loosen or broken sutures within
6 months of the surgery (Table 3). The duration of symptoms and
history of previous ocular surgery showed statistically significance
with the outcomes. 7 patients with more than 7 days of symptoms
did not recover the previous BCVA (p<0,001), developed new
rejections (p<0,006) and graft failure (p<0,001). 4 patients that
underwent phacoemulsification before penetrating keratoplasty
did not recover the previous BCVA (p<0,047) and developed
graft failure (p<0,047). The other characteristics such as gender,
eye (right or left), ocular patologies and systemic diseases did
no showed any statistically significant correlation with the
outcomes.
DISCUSSION
Current practices in the management of corneal graft
rejection still hold corticosteroids, in form of systemic or topical
therapy, as the gold standard in the treatment of acute graft
rejection and various routes of administrations have been
advocated, each with their merits and demerits(9). Systemic
corticosteroids should always be administered along with topical
corticosteroids. It reduces the number of circulating T cells and
inhibit their proliferation. In our study we use a intravenous pul-
se therapy dose of methyl prednisolone (500 mg in 100 ml of IV
fluid). The aim of the treatment is to induce transient lymphopenia
and gives rise to depletion of the helper cells(10). Since the anti-
inflammatory effect of the pulse therapy lasts up to 7 days, we
perform the second dose with one week interval. Pulse therapy
is beneficial in preventing subsequent rejection episodes. Since
there is no consensus about the best routes and doses of the
corticosteroid treatment for corneal graft rejections, identifying
the best treatment remains to be a challenging aspect in the graft
survival. Conditions like corneal vascularization, anterior synechia
and epithelial defect are well-known predisposing factors for graft
failure and rejection reactions(2). However our study did not find
statistically association between these risk factors and the
outcomes. This paradoxical observations can be due to a small
Outcomes > 7 Days Previous Corneal Ant. Epi.defect Loose/
of syntoms surgery vasc. Sinechia Broken suture
Without VA recovery and 7 (p <0.001) 4 (p>0.047) 2 (p<0.344) 3 (p<0.309) 4 (p< 0.256) 3 (p<0.205)
corneal edema regression
New rejections 7 (p<0.0060 4 (p<0.218) 4 (p<0.503) 5 (p<0.104) 5 (p<0.383) 6 (p<0.426)
Graft failure 7 (p<0.001) 4 (p<0,047) 2 (p<0.344) 3 (p<0.309) 4 (p<0.256) 3 (p<0.205)
Table 3
Outcomes
Demographic data Eyes
Eye Right 19
Left 13
Days of syntoms < 7 days 23
> 7 days 9
Previous ocular surgery Phacoemulsification 7
No 25
Ocular patology Glaucoma 4
Dry eye 1
Herpes 1
Trachoma 1
No 25
Systemic disease Hypertension 3
Diabetes 6
Steven Johnson 1
No 23
Corneal vascularization 0 20
1 quadrant 3
2 quadrants 4
3 quadrants 0
4 quadrants 5
Epithelial defect Yes 11
No 21
Anterior sinechia 0 24
1 quadrant 3
2 quadrants 4
3 quadrants 0
4 quadrants 1
Loose or broken suture Yes 18
No 14
Bilateral keratoplasty Yes 6
No 26
Table 2
Demographic data
Diagnosis Number of eyes (%)
Fuch’s distrophy 12 (37.5)
Corneal ulcer 11 (34.3)
Keratoconus  7 (21.8)
Herpetic keratitis 1   (3.1)
Steven Johnson syndrome 1   (3.1)
Table 1
Indications for PK
Abe RY, FreireLMD, Castro RS, Lira RPC, Arieta CEL
Rev Bras Oftalmol. 2013; 72 (1): 42-5
45
sample size and short follow up. In order to find a casual
relationship, a study with larger sample and longer follow-up is
required. Our study showed that eyes treated within less than 7
days of symptoms presented better BVCA recovery and fewer
recurrent rejections episodes (Table 3) and graft failure after
the treatment with the corticosteroid. Thus it is crucial to give the
patients proper education about the rejections symptoms and
also offer emergency medical assistance to allow quick diagnoses
and treatment of the rejection episode. Also, our case series
showed that eyes submitted to phacoemulsification previously
to PK, presented poor BCVA recovery and more graft failures,
suggesting that this procedure may worsen the prognostic of
corneal graft survival. Clinical studies are necessary in order to
investigate wether phacoemulsification or other anterior segment
surgery lead to more corneal rejection or graft failure rates.
CONCLUSION
Methylprednisolone (2 doses of 500 mg IV) in association
with topical prednisolone is an alternative treatment for graft
rejection. Our study showed that patients treated within 7 days
of symptoms and no previous anterior segment surgery had
better visual outcome and graft survival after treatment.
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